What MMT8 score indicates significant weakness in IIM?

MMT8 (8 proximal muscle groups bilaterally, max 80): score 60 = mild; 40-60 = moderate; <40 = severe; floor effect limits sensitivity in mild disease; CK, MRI, and functional assessments complement MMT8.

What autoantibodies guide IIM management?

Anti-MDA5 (CADM): high ILD risk, skin ulcers, rapidly progressive ILD requiring aggressive immunosuppression; Anti-Jo-1/ASyS: ILD, mechanic hands, Raynaud; Anti-TIF1γ: paraneoplastic DM (malignancy search essential); Anti-Mi-2: steroid-responsive classic DM.

What ILD surveillance is required for anti-MDA5 DM?

Anti-MDA5 associated with clinically amyopathic DM (CADM) and rapidly progressive ILD with 50% 6-month mortality; baseline and 1-3 monthly HRCT and PFTs; combination immunosuppression (cyclosporine + MMF + steroids) may prevent progression.

What malignancy work-up is indicated in dermatomyositis?

Anti-TIF1γ positive DM has 30-50% malignancy association; CT chest/abdomen/pelvis, mammography, cervical smear, PSA at diagnosis; PET-CT for high-risk patients; malignancy work-up should be repeated annually for 3-5 years.

How is inclusion body myositis distinguished from PM?

IBM: onset >50 years, finger flexor and quadriceps weakness preferentially, dysphagia, rimmed vacuoles on biopsy, anti-NT5C1A antibodies, very slowly progressive, corticosteroid-resistant; PM: younger, proximal symmetric weakness, steroid-responsive.

Inflammatory Myopathy (IIM) Disease Activity Assessment

Assesses inflammatory myopathy (DM/PM/IBM/ASyS) disease activity using MMT8 manual muscle testing, MDAAT, skin VAS, CK levels, and IIM-specific autoantibody-guided prognosis (anti-MDA5, anti-Jo-1).

Use the full interactive calculator below, or

Related Calculators

BVAS Score

Medical Calculators

DAS28-CRP

Medical Calculators

SSc mRSS Score

Medical Calculators

Inflammatory Myopathy (IIM) Disease Activity Assessment

Related Calculators

Frequently Asked Questions

What MMT8 score indicates significant weakness in IIM?

What autoantibodies guide IIM management?

What ILD surveillance is required for anti-MDA5 DM?

What malignancy work-up is indicated in dermatomyositis?

How is inclusion body myositis distinguished from PM?